SHANK3 and beta-synuclein are novel blood-based biomarkers for the Phelan-McDermid Syndrome: a pilot study.

Transl Psychiatry · 2026 · PMC13039877 · PMID 41876457

Europe PMC DOI

hedged sentence

0.0820

closest p · 1.6× alpha

0.0820

boldest claim

The sentences

a suggestive trendp = 0.082so close (0.05 < p ≤ 0.1)

For regression, SHANK3 showed a negative effect (p = 0.05) and the interaction term showed a suggestive trend (p = 0.082).

also in 203 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.